Waldenström Macroglobulinemia: FDA Updates

August 27, 2018 – The U.S. Food and Drug Administration (FDA) approved ibrutinib (IMBRUVICA) plus rituximab (RITUXAN) for the first chemotherapy-free treatment for adult patients with Waldenstrom’s macroglobulinemia (WM). More Information.